1. Prevention and treatment of tuberculosis infection in candidates for biologic therapy: A multidisciplinary consensus statement adapted to the dermatology patient.
- Author
-
Rodríguez-Jiménez P, Mir-Viladrich I, Chicharro P, Solano-López G, López-Longo FJ, Taxonera C, Sánchez-Martínez P, Martínez-Lacasa X, García-Gasalla M, Dorca J, Arias-Guillén M, García-García JM, and Dauden E
- Subjects
- Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal therapeutic use, Antitubercular Agents administration & dosage, Drug Monitoring, Hidradenitis Suppurativa drug therapy, Humans, Immunity, Cellular, Latent Tuberculosis diagnosis, Patient Selection, Psoriasis drug therapy, Risk, T-Lymphocyte Subsets immunology, Tuberculosis drug therapy, Tumor Necrosis Factor-alpha antagonists & inhibitors, Antitubercular Agents therapeutic use, Biological Therapy adverse effects, Latent Tuberculosis drug therapy, Tuberculosis prevention & control
- Abstract
Patients with chronic inflammatory diseases being treated with immunosuppressive drugs, and with tumor necrosis factor inhibitors in particular, have an increased risk of infection by Mycobacterium tuberculosis. Screening for latent tuberculosis infection and preventive therapy to reduce the risk of progression to active tuberculosis are mandatory in this group of patients. This updated multidisciplinary consensus document presents the latest expert opinions on the treatment and prevention of tuberculosis in candidates for biologic therapy and establishes recommendations based on current knowledge relating to the use of biologic agents., (Copyright © 2018 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF